XT
ATHE

XTX Topco’s Alterity Therapeutics ATHE Stock Holding History

XTX Topco’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,425
Closed -$35.7K – 1853
2024
Q1 		$35.7K Buy
+17,425
New +$33.6K ﹤0.01% 1527

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
PCA
Providence Capital Advisors Charlotte, North Carolina $613M AUM 17.83% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SWM
Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco's ATHE Position: Q2 2024 in Review

XTX Topco sold out of Alterity Therapeutics (ATHE) in Q2 2024, closing a stake of 17,425 shares — an estimated $35.7K sold.

XTX Topco first reported a position in ATHE in Q1 2024 and held it in 1 quarter. The position peaked at $35.7K in Q1 2024. 10 funds tracked by Wall St. Rank hold ATHE as of Q2 2024.

  • XTX Topco reported no remaining Alterity Therapeutics position as of Q2 2024 after selling out during the quarter.
  • XTX Topco sold 17,425 Alterity Therapeutics shares in Q2 2024, an estimated $35.7K.
  • XTX Topco first reported a position in Alterity Therapeutics in Q1 2024 and held it in 1 quarter.
  • XTX Topco's Alterity Therapeutics position peaked at $35.7K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2024.

Based on XTX Topco's 13F filing for Q2 2024, filed 12 Aug 2024.